All News

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses his presentation at the American Society of Nephrology’s Kidney Week 2021 on vascular aging in chronic kidney disease.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how chronic kidney disease elevated the risk of vascular calcification and what the risks of vascular calcification are.

In a clinical study of healthy adults, Dyanavel XR tablets were deemed to be bioequivalent to amphetamine extended-release oral suspension in patients with ADHD.

Dr. Cary Boyd-Shiwarski explains how nonsteroidal mineralcorticoid receptor antagonists and novel potassium-binding agents alter the management of hyperkalemia and approaching potassium handling in chronic kidney disease.

Drug dose and monitoring should be individualized based on patients’ unique bone marrow health profile with their age, comorbidities, and prior marrow toxic drug use accounted for.

In addition to the vital clinical role that pharmacists play, Mei Ka Fong, PharmD, BCOP, said pharmacists are essential to ensuring that patients understand their disease and their treatments.

Boyd gave a general overview of how potassium handling works in chronic kidney disease, specifically with hyperkalemia.

Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, discusses the common health impacts of phosphate metabolism disorders.

Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, discusses the relationship between chronic kidney disease and disorders of phosphate metabolism.

Despoina Manousaki, MD, PhD, pediatric endocrinologist and assistant professor at CHU Sainte-Justine Research Centre, discusses the relationship between uremia and chronic kidney disease.

Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses next steps in research investigating the benefits of aspirin in patients with chronic kidney disease.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses some best clinical practices for psychedelic-assisted therapy in terms of assessing pharmacological profile.

Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, why submaximal dosing is important in minimizing proteinuria and chronic kidney disease.

Tidutamab was found to have favorable safety and tolerability treating neuroendocrine tumors of pancreatic, gastrointestinal, lung, and undetermined origin.

Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the implications of study results assessing long-term aspirin use and the progression of kidney disease.

Mei Ka Fong, PharmD, BCOP, said that although many potential adverse events are well understood in patients receiving traditional treatments, there are no studies investigating the sequencing of these agents.

Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, discusses what the study results demonstrated regarding treating carcinoid crisis without perioperative octreotide for patients with neuroendocrine tumors.

Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the study findings regarding how the long-term use of aspirin impacts mortality and renal deterioration in patients with chronic kidney disease.

Structural changes to the COVID-19 virus highlight the need to expand the research efforts.

Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses what patient populations were included in the study assessing the long-term use of aspirin in patients with chronic kidney disease.

Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, discusses what the study results demonstrated regarding treating carcinoid crisis without perioperative octreotide for patients with neuroendocrine tumors.

In this first episode of the new series, Executive Director of the Chacruna Institute Bia Labate, PhD, and Kelan Thomas, PharmD, MS, associate professor of clinical sciences at the Touro University California College of Pharmacy, discussed the global psychedelic medicine market.

Dulcolax, for the relief of occasional constipation, contains lactose and sucrose.

Dulaglutide is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Symptoms of classic Fabry disease appear during childhood or the teenage years.

Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, why providers might under dose ACE and ARB treatments for proteinuria.

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses the selection of the patient populations included in the study of carcinoid crisis with no perioperative octreotide.

Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the established understanding of how the use of aspirin impacts the treatment of chronic kidney disease.